CIB vs INCY Comparison

Grupo Cibest SA formerly BanColombia SA is a financial services company. A conglomerate of financial institutions, BanColombia offers a wide range of product offerings and financial services, including loans to small and midsize enterprises and governments, leasing, factoring, and asset management. The company's operations are in Colombia, Panama, El Salvador, the United States of America, Puerto Rico, Bermuda, and Guatemala. The Bank has the following segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking and All other segments. The majority of revenue is generated from the Banking Colombia segment.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.